MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK, et al.; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int69: 1945–1953, 2006PubMed
MoeS, DrüekeT, CunninghamJ, GoodmanW, MartinK, OlgaardK, ; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int69: 1945–1953, 2006PubMed10.1038/sj.ki.5000414)| false
HuMC, ShiM, MoeOW: Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters. Pflugers Arch471: 99–108, 2019PubMed10.1007/s00424-018-2238-5)| false
Urena TorresP, FriedlanderG, de VernejoulMC, SilveC, PriéD: Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int73: 102–107, 2008PubMed
Urena TorresP, FriedlanderG, de VernejoulMC, SilveC, PriéD: Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int73: 102–107, 2008PubMed10.1038/sj.ki.5002622)| false
IsakovaT, CaiX, LeeJ, KatzR, CauleyJA, FriedLF, et al.; Health ABC Study: Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals. J Bone Miner Res31: 742–748, 2016PubMed
IsakovaT, CaiX, LeeJ, KatzR, CauleyJA, FriedLF, ; Health ABC Study: Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals. J Bone Miner Res31: 742–748, 2016PubMed10.1002/jbmr.2750)| false
ManghatP, FraserWD, WierzbickiAS, FogelmanI, GoldsmithDJ, HampsonG: Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int21: 1853–1861, 2010PubMed
ManghatP, FraserWD, WierzbickiAS, FogelmanI, GoldsmithDJ, HampsonG: Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int21: 1853–1861, 2010PubMed10.1007/s00198-009-1142-4)| false
KandaE, YoshidaM, SasakiS: Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients. BMC Nephrol13: 122, 2012PubMed
KandaE, YoshidaM, SasakiS: Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients. BMC Nephrol13: 122, 2012PubMed10.1186/1471-2369-13-122)| false
DesbiensLC, SidibéA, UngRV, FortierC, MungerM, WangYP, et al.: FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study. Osteoporos Int29: 2345–2353, 2018PubMed
Ben-DovIZ, GalitzerH, Lavi-MoshayoffV, GoetzR, Kuro-oM, MohammadiM, et al.: The parathyroid is a target organ for FGF23 in rats. J Clin Invest117: 4003–4008, 2007PubMed
Ben-DovIZ, GalitzerH, Lavi-MoshayoffV, GoetzR, Kuro-oM, MohammadiM, : The parathyroid is a target organ for FGF23 in rats. J Clin Invest117: 4003–4008, 2007PubMed)| false
MaceML, GravesenE, NordholmA, OlgaardK, LewinE: Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo Through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia. Calcif Tissue Int102: 85–92, 2018PubMed
MaceML, GravesenE, NordholmA, OlgaardK, LewinE: Fibroblast Growth Factor (FGF) 23 Regulates the Plasma Levels of Parathyroid Hormone In Vivo Through the FGF Receptor in Normocalcemia, But Not in Hypocalcemia. Calcif Tissue Int102: 85–92, 2018PubMed10.1007/s00223-017-0333-9)| false
KrajisnikT, OlausonH, MirzaMA, HellmanP, AkerströmG, WestinG, et al.: Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int78: 1024–1032, 2010PubMed
RheeY, BiviN, FarrowE, LezcanoV, PlotkinLI, WhiteKE, et al.: Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone49: 636–643, 2011
RheeY, BiviN, FarrowE, LezcanoV, PlotkinLI, WhiteKE, : Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone49: 636–643, 201110.1016/j.bone.2011.06.025)| false
ChaudharyLR, HofmeisterAM, HruskaKA: Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone34: 402–411, 2004PubMed
ChaudharyLR, HofmeisterAM, HruskaKA: Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone34: 402–411, 2004PubMed10.1016/j.bone.2003.11.014)| false
GonzálezEA, LundRJ, MartinKJ, McCartneyJE, TondraviMM, SampathTK, et al.: Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int61: 1322–1331, 2002PubMed
GonzálezEA, LundRJ, MartinKJ, McCartneyJE, TondraviMM, SampathTK, : Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int61: 1322–1331, 2002PubMed10.1046/j.1523-1755.2002.00258.x)| false
LundRJ, DaviesMR, BrownAJ, HruskaKA: Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol15: 359–369, 2004PubMed
LundRJ, DaviesMR, BrownAJ, HruskaKA: Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol15: 359–369, 2004PubMed10.1097/01.ASN.0000109671.99498.08)| false
MasuyamaR, StockmansI, TorrekensS, Van LooverenR, MaesC, CarmelietP, et al.: Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest116: 3150–3159, 2006PubMed
MasuyamaR, StockmansI, TorrekensS, Van LooverenR, MaesC, CarmelietP, : Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest116: 3150–3159, 2006PubMed10.1172/JCI29463)| false
LiuS, TangW, ZhouJ, StubbsJR, LuoQ, PiM, et al.: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol17: 1305–1315, 2006PubMed
SpragueSM, WetmoreJB, GurevichK, Da RozaG, BuerkertJ, ReinerM, et al.: Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol10: 1021–1030, 2015PubMed
SpragueSM, WetmoreJB, GurevichK, Da RozaG, BuerkertJ, ReinerM, : Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol10: 1021–1030, 2015PubMed10.2215/CJN.03270314)| false
LiuH, FergussonMM, CastilhoRM, LiuJ, CaoL, ChenJ, et al.: Augmented Wnt signaling in a mammalian model of accelerated aging. Science317: 803–806, 2007PubMed
SakaiR, FujitaS, HorieT, OhyamaT, MiwaK, MakiT, et al.: Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone27: 91–96, 2000PubMed
SakaiR, FujitaS, HorieT, OhyamaT, MiwaK, MakiT, : Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone27: 91–96, 2000PubMed10.1016/S8756-3282(00)00307-0)| false
VerzolaD, BarisioneC, PicciottoD, GaribottoG, KoppeL: Emerging role of myostatin and its inhibition in the setting of chronic kidney disease. Kidney Int95: 506–517, 2019PubMed
VerzolaD, BarisioneC, PicciottoD, GaribottoG, KoppeL: Emerging role of myostatin and its inhibition in the setting of chronic kidney disease. Kidney Int95: 506–517, 2019PubMed10.1016/j.kint.2018.10.010)| false
LimaF, MawadH, El-HusseiniAA, DavenportDL, MallucheHH: Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers. Clin Nephrol91: 222–230, 2019PubMed
LimaF, MawadH, El-HusseiniAA, DavenportDL, MallucheHH: Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers. Clin Nephrol91: 222–230, 2019PubMed10.5414/CN109650)| false
LotinunS, PearsallRS, DaviesMV, MarvellTH, MonnellTE, UcranJ, et al.: A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone46: 1082–1088, 2010PubMed
LotinunS, PearsallRS, DaviesMV, MarvellTH, MonnellTE, UcranJ, : A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone46: 1082–1088, 2010PubMed10.1016/j.bone.2010.01.370)| false
RuckleJ, JacobsM, KramerW, PearsallAE, KumarR, UnderwoodKW, et al.: Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res24: 744–752, 2009PubMed
WilliamsMJ, SugataniT, AgapovaOA, FangY, GautJP, FaugereMC, et al.: The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int93: 147–158, 2018PubMed
WilliamsMJ, SugataniT, AgapovaOA, FangY, GautJP, FaugereMC, : The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int93: 147–158, 2018PubMed10.1016/j.kint.2017.06.016)| false
SugataniT, AgapovaOA, FangY, BermanAG, WallaceJM, MallucheHH, et al.: Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney Int91: 86–95, 2017PubMed
SugataniT, AgapovaOA, FangY, BermanAG, WallaceJM, MallucheHH, : Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease. Kidney Int91: 86–95, 2017PubMed10.1016/j.kint.2016.07.039)| false
AgapovaOA, FangY, SugataniT, SeifertME, HruskaKA: Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int89: 1231–1243, 2016PubMed
AgapovaOA, FangY, SugataniT, SeifertME, HruskaKA: Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int89: 1231–1243, 2016PubMed10.1016/j.kint.2016.02.002)| false
BushinskyDA: Acidosis and renal bone disease. In: The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease, edited by OlgaardK, SaluskyIB, SilverJ, Oxford, Oxford University Press, 2010, pp 253–265
BushinskyDA: Acidosis and renal bone disease. In: The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease, edited by OlgaardK, SaluskyIB, SilverJ, Oxford, Oxford University Press, 2010, pp 253–26510.1093/med/9780199559176.003.015)| false
JorgettiV, DrüekeTB, OttSM: Role of proton receptor OGR1 in bone response to metabolic acidosis?Kidney Int89: 529–531, 2016PubMed10.1016/j.kint.2015.12.031)| false
KriegerNS, YaoZ, Kyker-SnowmanK, KimMH, BoyceBF, BushinskyDA: Increased bone density in mice lacking the proton receptor OGR1. Kidney Int89: 565–573, 2016PubMed
DoumouchtsisKK, KostakisAI, DoumouchtsisSK, GrapsaEI, PassalidouIA, TziamalisMP, et al.: The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. Hemodial Int12: 100–107, 2008PubMed
DoumouchtsisKK, KostakisAI, DoumouchtsisSK, GrapsaEI, PassalidouIA, TziamalisMP, : The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. Hemodial Int12: 100–107, 2008PubMed10.1111/j.1542-4758.2008.00249.x)| false
AlbaajF, SivalinghamM, HaynesP, McKinnonG, FoleyRN, WaldekS, et al.: Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J82: 693–696, 2006PubMed
AlbaajF, SivalinghamM, HaynesP, McKinnonG, FoleyRN, WaldekS, : Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J82: 693–696, 2006PubMed10.1136/pgmj.2006.045963)| false
KhuranaKK, NavaneethanSD, ArrigainS, ScholdJD, NallyJVJr, ShoskesDA: Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis64: 367–374, 2014PubMed
KhuranaKK, NavaneethanSD, ArrigainS, ScholdJD, NallyJVJr, ShoskesDA: Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis64: 367–374, 2014PubMed10.1053/j.ajkd.2014.03.010)| false
AleksovaJ, RodriguezAJ, McLachlanR, KerrP, MilatF, EbelingPR: Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis. Curr Osteoporos Rep16: 674–692, 2018PubMed
AleksovaJ, RodriguezAJ, McLachlanR, KerrP, MilatF, EbelingPR: Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis. Curr Osteoporos Rep16: 674–692, 2018PubMed10.1007/s11914-018-0483-3)| false
CarreroJJ, QureshiAR, NakashimaA, ArverS, PariniP, LindholmB, et al.: Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant26: 184–190, 2011PubMed
ShanbhogueVV, HansenS, FrostM, BrixenK, HermannAP: Bone disease in diabetes: another manifestation of microvascular disease?Lancet Diabetes Endocrinol5: 827–838, 2017PubMed
ShanbhogueVV, HansenS, FrostM, BrixenK, HermannAP: Bone disease in diabetes: another manifestation of microvascular disease?Lancet Diabetes Endocrinol5: 827–838, 2017PubMed10.1016/S2213-8587(17)30134-1)| false
HoldenRM, MortonAR, GarlandJS, PavlovA, DayAG, BoothSL: Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol5: 590–597, 2010PubMed
HoldenRM, MortonAR, GarlandJS, PavlovA, DayAG, BoothSL: Vitamins K and D status in stages 3-5 chronic kidney disease. Clin J Am Soc Nephrol5: 590–597, 2010PubMed10.2215/CJN.06420909)| false
CranenburgEC, SchurgersLJ, UiterwijkHH, BeulensJW, DalmeijerGW, WesterhuisR, et al.: Vitamin K intake and status are low in hemodialysis patients. Kidney Int82: 605–610, 2012PubMed
CranenburgEC, SchurgersLJ, UiterwijkHH, BeulensJW, DalmeijerGW, WesterhuisR, : Vitamin K intake and status are low in hemodialysis patients. Kidney Int82: 605–610, 2012PubMed10.1038/ki.2012.191)| false
McCabeKM, BoothSL, FuX, ShobeiriN, PangJJ, AdamsMA, et al.: Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int83: 835–844, 2013PubMed
McCabeKM, BoothSL, FuX, ShobeiriN, PangJJ, AdamsMA, : Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int83: 835–844, 2013PubMed10.1038/ki.2012.477)| false
WestenfeldR, KruegerT, SchlieperG, CranenburgEC, MagdeleynsEJ, HeidenreichS, et al.: Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis59: 186–195, 2012PubMed
WestenfeldR, KruegerT, SchlieperG, CranenburgEC, MagdeleynsEJ, HeidenreichS, : Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis59: 186–195, 2012PubMed10.1053/j.ajkd.2011.10.041)| false
LauWCY, CheungCL, ManKKC, ChanEW, SingCW, LipGYH, et al.: Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study. Ann Intern Med173: 1–9, 2020PubMed
LauWCY, CheungCL, ManKKC, ChanEW, SingCW, LipGYH, : Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study. Ann Intern Med173: 1–9, 2020PubMed10.7326/M19-3671)| false
KiepeD, TönshoffB: Insulin-like growth factors in normal and diseased kidney. Endocrinol Metab Clin North Am41: 351–374, vii, 2012[vii.]PubMed10.1016/j.ecl.2012.04.015)| false
HanDS, ChenYM, LinSY, ChangHH, HuangTM, ChiYC, et al.: Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin Endocrinol (Oxf)75: 857–863, 2011PubMed
OttSM, MaloneyNA, CoburnJW, AlfreyAC, SherrardDJ: The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med307: 709–713, 1982PubMed
OttSM, MaloneyNA, CoburnJW, AlfreyAC, SherrardDJ: The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med307: 709–713, 1982PubMed10.1056/NEJM198209163071202)| false
CarbonaraCEM, ReisLMD, QuadrosKRDS, RozaNAV, SanoR, CarvalhoAB, et al.: Renal osteodystrophy and clinical outcomes: data from the Brazilian Registry of Bone Biopsies - REBRABO. J Bras Nefrol42: 138–146, 2020PubMed
CarbonaraCEM, ReisLMD, QuadrosKRDS, RozaNAV, SanoR, CarvalhoAB, : Renal osteodystrophy and clinical outcomes: data from the Brazilian Registry of Bone Biopsies - REBRABO. J Bras Nefrol42: 138–146, 2020PubMed10.1590/2175-8239-jbn-2019-0045)| false
McCarthyJT, HodgsonSF, FairbanksVF, MoyerTP: Clinical and histologic features of iron-related bone disease in dialysis patients. Am J Kidney Dis17: 551–561, 1991PubMed
McCarthyJT, HodgsonSF, FairbanksVF, MoyerTP: Clinical and histologic features of iron-related bone disease in dialysis patients. Am J Kidney Dis17: 551–561, 1991PubMed10.1016/S0272-6386(12)80497-5)| false
YangQ, JianJ, AbramsonSB, HuangX: Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res26: 1188–1196, 2011PubMed
YangQ, JianJ, AbramsonSB, HuangX: Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res26: 1188–1196, 2011PubMed10.1002/jbmr.337)| false
SchrootenI, BehetsGJ, CabreraWE, VercauterenSR, LambertsLV, VerberckmoesSC, et al.: Dose-dependent effects of strontium on bone of chronic renal failure rats. Kidney Int63: 927–935, 2003PubMed
ChavassieuxP, MeunierPJ, RouxJP, Portero-MuzyN, PierreM, ChapurlatR: Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women. Randomized comparison to alendronate. J Bone Miner Res: 29: 618–628, 2014PubMed
ChavassieuxP, MeunierPJ, RouxJP, Portero-MuzyN, PierreM, ChapurlatR: Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women. Randomized comparison to alendronate. J Bone Miner Res: 29: 618–628, 2014PubMed10.1002/jbmr.2074)| false
DempsterDW, CompstonJE, DreznerMK, GlorieuxFH, KanisJA, MallucheH, et al.: Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res28: 2–17, 2013PubMed
DempsterDW, CompstonJE, DreznerMK, GlorieuxFH, KanisJA, MallucheH, : Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res28: 2–17, 2013PubMed10.1002/jbmr.1805)| false
National Kidney Foundation. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-CKD-MBD-Guideline-English.pdf. Accessed December 10, 2020
National Kidney Foundation. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-CKD-MBD-Guideline-English.pdf. Accessed December 10, 2020)| false
Paton‐HoughJ, TazzymanS, EvansH, LathD, DownJM, GreenAC, et al.: Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. J Bone Miner Res34:783–796, 2018
Paton‐HoughJ, TazzymanS, EvansH, LathD, DownJM, GreenAC, : Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. J Bone Miner Res34:783–796, 201810.1002/jbmr.3606)| false
GlorieuxFH, TraversR, TaylorA, BowenJR, RauchF, NormanM, et al.: Normative data for iliac bone histomorphometry in growing children. Bone26: 103–109, 2000PubMed
GlorieuxFH, TraversR, TaylorA, BowenJR, RauchF, NormanM, : Normative data for iliac bone histomorphometry in growing children. Bone26: 103–109, 2000PubMed10.1016/S8756-3282(99)00257-4)| false
ParisienM, CosmanF, MorganD, SchnitzerM, LiangX, NievesJ, et al.: Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. J Bone Miner Res12: 948–957, 1997PubMed
ParisienM, CosmanF, MorganD, SchnitzerM, LiangX, NievesJ, : Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. J Bone Miner Res12: 948–957, 1997PubMed10.1359/jbmr.1997.12.6.948)| false
ReckerRR, KimmelDB, ParfittAM, DaviesKM, KeshawarzN, HindersS: Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res3: 133–144, 1988PubMed
ReckerRR, KimmelDB, ParfittAM, DaviesKM, KeshawarzN, HindersS: Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res3: 133–144, 1988PubMed10.1002/jbmr.5650030203)| false
MallucheHH, MawadHW, Monier-FaugereMC: Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res26: 1368–1376, 2011PubMed
MallucheHH, MawadHW, Monier-FaugereMC: Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res26: 1368–1376, 2011PubMed10.1002/jbmr.309)| false
HanZH, PalnitkarS, RaoDS, NelsonD, ParfittAM: Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res12: 498–508, 1997PubMed
HanZH, PalnitkarS, RaoDS, NelsonD, ParfittAM: Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res12: 498–508, 1997PubMed10.1359/jbmr.1997.12.4.498)| false
AllenMR, McNernyEM, OrganJM, WallaceJM: True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo. J Bone Miner Res30: 1539–1550, 2015PubMed
AllenMR, McNernyEM, OrganJM, WallaceJM: True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo. J Bone Miner Res30: 1539–1550, 2015PubMed10.1002/jbmr.2603)| false
GerakisA, HadjidakisD, KokkinakisE, ApostolouT, RaptisS, BillisA: Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol13: 437–443, 2000PubMed
GerakisA, HadjidakisD, KokkinakisE, ApostolouT, RaptisS, BillisA: Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol13: 437–443, 2000PubMed)| false
AraújoSM, AmbrosoniP, LobãoRR, CaorsiH, MoysésRM, BarretoFC, et al.: The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl (85): S54–S56, 2003PubMed
AraújoSM, AmbrosoniP, LobãoRR, CaorsiH, MoysésRM, BarretoFC, : The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl (85): S54–S56, 2003PubMed10.1046/j.1523-1755.63.s85.13.x)| false
National Kidney Foundation.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Available at https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf. Accessed December 10, 2020
National Kidney Foundation.Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Available at https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf. Accessed December 10, 2020)| false
SalamS, GallagherO, GossielF, PaggiosiM, KhwajaA, EastellR: Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. J Am Soc Nephrol29: 1557–1565, 2018PubMed
SalamS, GallagherO, GossielF, PaggiosiM, KhwajaA, EastellR: Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. J Am Soc Nephrol29: 1557–1565, 2018PubMed10.1681/ASN.2017050584)| false
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA, et al.: Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis67: 559–566, 2016PubMed
SpragueSM, Bellorin-FontE, JorgettiV, CarvalhoAB, MallucheHH, FerreiraA, : Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis67: 559–566, 2016PubMed10.1053/j.ajkd.2015.06.023)| false
AaltonenL, KoivuviitaN, SeppänenM, TongX, KrögerH, LöyttyniemiE, et al.: Correlation between 18F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone134: 115267, 2020PubMed
EvenepoelP, D’HaeseP, BacchettaJ, Cannata-AndiaJ, FerreiraA, HaarhausM, et al.; ERA-EDTA Working Group on CKD-MBD: Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. Nephrol Dial Transplant32: 1608–1613, 2017PubMed
EvenepoelP, D’HaeseP, BacchettaJ, Cannata-AndiaJ, FerreiraA, HaarhausM, ; ERA-EDTA Working Group on CKD-MBD: Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper. Nephrol Dial Transplant32: 1608–1613, 2017PubMed)| false
MoeSM, AbdallaS, ChertowGM, ParfreyPS, BlockGA, Correa-RotterR, et al.; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators: Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol26: 1466–1475, 2015PubMed
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis56: 57–68, 2010PubMed
ToussaintND, LauKK, StraussBJ, PolkinghorneKR, KerrPG: Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis56: 57–68, 2010PubMed10.1053/j.ajkd.2009.12.039)| false
